Page last updated: 2024-12-07
3'-o-methyl-nordihydroguaiaretic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
heminordihydroguaiaretic acid: RN given refers to cpd without isomeric designation; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 122821 |
| CHEMBL ID | 400065 |
| SCHEMBL ID | 13309003 |
| MeSH ID | M0125111 |
Synonyms (19)
| Synonym |
|---|
| (+)-4-[4-(4-hydroxy-3-methoxy-phenyl)-2,3-dimethyl-butyl]-benzene-1,2-diol |
| (+/-)-4-[4-(4-hydroxy-3-methoxy-phenyl)-2,3-dimethyl-butyl]-benzene-1,2-diol |
| mal.4 |
| 3-o'-methyl-ndga |
| 54473-24-4 |
| 1-(3,4-dihydroxyphenyl)-4-(3-methoxy-4-hydroxyphenyl)-2,3dimethylbutane |
| 3-o'-methyl nordihydroguaiaretic acid |
| 4-[(2r,3s)-4-(4-hydroxy-3-methoxy-phenyl)-2,3-dimethyl-butyl]benzene-1,2-diol |
| heminordihydroguaiaretic acid |
| CHEMBL400065 |
| 1,2-benzenediol, 4-(4-(4-hydroxy-3-methoxyphenyl)-2,3-dimethylbutyl)- |
| hemi-ndga |
| 3'-o-methyl-nordihydroguaiaretic acid |
| malachi 4 5-6 |
| 3'-o-methyl-ndga |
| SCHEMBL13309003 |
| QKHJBWUGXMKHAK-OLZOCXBDSA-N |
| 4-[4-(4-hydroxy-3-methoxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol |
| DTXSID60969644 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (2)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID313419 | Antioxidant activity assessed as inhibition of LDL-oxidation at 20 uM by TBARS assay | 2008 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1 | Low-density lipoprotein (LDL)-antioxidant lignans from Myristica fragrans seeds. |
| AID313420 | Antioxidant activity against LDL-oxidation by TBARS assay | 2008 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1 | Low-density lipoprotein (LDL)-antioxidant lignans from Myristica fragrans seeds. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.56
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||